IN8bio Completes Dosing of First Cohort in Phase I Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

IN8bio, Inc. announced completion of dosing of the first patient cohort in a Phase I clinical trial of INB-100, a donor-derived gamma-delta T cell therapeutic in development for patients with leukemia undergoing haploidentical stem cell transplant.